IA
ALXN

IFP Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

IFP Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-240
Closed -$45K – 3517
2021
Q2 		$45K Buy
240
+23
+11% +$3.95K ﹤0.01% 1576
2021
Q1 		$32K Sell
217
-43
-17% -$6.65K ﹤0.01% 1640
2020
Q4 		$40K Sell
260
-1
-0.4% -$129 ﹤0.01% 1531
2020
Q3 		$30K Sell
261
-37
-12% -$3.99K ﹤0.01% 1484
2020
Q2 		$33K Sell
298
-13
-4% -$1.38K ﹤0.01% 1390
2020
Q1 		$26K Buy
311
+7
+2% +$687 ﹤0.01% 1392
2019
Q4 		$32K Buy
304
+54
+22% +$5.78K ﹤0.01% 1435
2019
Q3 		$24K Buy
+250
New +$28.2K ﹤0.01% 1700
2019
Q1 		$4K Sell
34
-318
-90% -$39.5K ﹤0.01% 1962
2018
Q4 		$34K Buy
352
+79
+29% +$9.34K ﹤0.01% 1836
2018
Q3 		$38K Sell
273
-41
-13% -$5.14K ﹤0.01% 2054
2018
Q2 		$39K Sell
314
-484
-61% -$56.6K ﹤0.01% 2077
2018
Q1 		$95K Hold
798
– – ﹤0.01% 1418
2017
Q4 		$95K Buy
798
+154
+24% +$18.8K ﹤0.01% 1430
2017
Q3 		$90K Buy
644
+208
+48% +$28.3K ﹤0.01% 1621
2017
Q2 		$53K Sell
436
-74
-15% -$8.61K ﹤0.01% 1935
2017
Q1 		$62K Sell
510
-17
-3% -$2.19K ﹤0.01% 1802
2016
Q4 		$64K Buy
527
+51
+11% +$6.24K ﹤0.01% 1742
2016
Q3 		$58K Buy
476
+68
+17% +$8.75K ﹤0.01% 1721
2016
Q2 		$48K Buy
408
+374
+1,100% +$53.1K ﹤0.01% 1791
2016
Q1 		$4K Sell
34
-129
-79% -$18.9K ﹤0.01% 1954
2015
Q4 		$31K Buy
+163
New +$28.5K ﹤0.01% 1900

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

IFP Advisors's ALXN Position: Q3 2021 in Review

IFP Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 240 shares — an estimated $45K sold.

IFP Advisors first reported a position in ALXN in Q4 2015 and held it in 22 quarters. The position peaked at $95K in Q1 2018. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • IFP Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • IFP Advisors sold 240 Alexion Pharmaceuticals shares in Q3 2021, an estimated $45K.
  • IFP Advisors first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 22 quarters.
  • IFP Advisors's Alexion Pharmaceuticals position peaked at $95K in Q1 2018.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on IFP Advisors's 13F filing for Q3 2021, filed 6 Oct 2021.